Evidence map›Paper›PMID 40572939›Full record

ArticleMaterials (Basel, Switzerland)2025

Effect of a Recycled Phosphogypsum Modifier on the Performance of High-Content Phosphogypsum Cementing Materials.

Jiuyang Lian, Chiqiu Wu, Zhonghe Shui, Wei Lyu

Abstract read
In one paragraph

Article in Materials (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jiuyang LianSchool of Materials Science and Engineering, Wuhan University of Technology, Wuhan 430070, China.
Chiqiu WuHubei Changyao New Materials Co., Ltd., Yichang 443000, China.
Zhonghe ShuiState Key Laboratory of Silicate Materials for Architectures, Wuhan University of Technology, Wuhan 430070, China.
Wei LyuHubei Changyao New Materials Co., Ltd., Yichang 443000, China.

Funding

Hubei Changyao New Materials Co., Ltd., China 20221h0534Hubei Changyao New Materials Co., Ltd., China 202301hx0503
6 · The paper itself

Abstract

Phosphogypsum, a byproduct of phosphate fertilizer production, represents a significant environmental concern due to its large-scale production and low utilization rates. Although preparing phosphogypsum-based cementitious materials offers a potential solution to these issues, high-content phosphogypsum cementitious systems encounter significant technical barriers, including long setting durations and insufficient early-age strength development, thereby restricting their practical implementation. Hence, this research developed innovative modifiers through an environmentally friendly low-temperature thermal activation process (100-160 °C) utilizing recycled phosphogypsum aggregates and circumventing the substantial carbon emissions associated with conventional modification approaches. Systematic characterization demonstrated that the dehydration phase modifier synthesized at 120 °C (DH120) exhibited optimal phase composition, resulting in a 35.7% enhancement in its 14-d compressive strength (9.8 MPa vs. 7.2 MPa for the control) and an 11.3% reduction in its initial setting time (27.5 vs. 31.0 h for the control). Microstructural characterization by low-field nuclear magnetic resonance and X-ray diffractometry revealed that DH120 effectively enhanced refinement of the pore structure (37.7% mesopore volume reduction) and promoted the ettringite crystallization kinetics. This work establishes a sustainable framework for utilizing industrial byproducts in cementitious material systems.

Indexed as

crystal seeddehydration phasesearly strengthhigh-content phosphogypsumsetting time

Identifiers

PMID40572939
PMCPMC12195041

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.